Beijing Dentons Law Offices
Supplementary Legal Opinion (I) on the Major Asset Purchase by Wuhan Mingde Bio-Tech Co., Ltd.
Dentons Securities No. [2026] 132-4
To: Wuhan Mingde Bio-Tech Co., Ltd.
Pursuant to the "Special Legal Counsel Contract" signed between Wuhan Mingde Bio-Tech Co., Ltd. (hereinafter referred to as the "Company") and Beijing Dentons Law Offices (hereinafter referred to as "this Firm"), this Firm was engaged by the listed company to serve as special legal counsel for its major asset purchase project. This Firm has previously issued the "Beijing Dentons Law Offices Legal Opinion on the Major Asset Purchase by Wuhan Mingde Bio-Tech Co., Ltd." (Dentons Securities No. [2026] 132, hereinafter referred to as the "Legal Opinion").
On July 10, 2026, the Shenzhen Stock Exchange issued the "Inquiry Letter on the Merger and Reorganization of Wuhan Mingde Bio-Tech Co., Ltd." (hereinafter referred to as the "Inquiry Letter") to inquire about matters related to this major asset reorganization. Simultaneously, the audit reference date for the financial data of the listed company's major asset reorganization was adjusted to March 31, 2026, and the reporting period for this supplementary legal opinion was adjusted to the years 2024, 2025, and the period from January to March 2026 (hereinafter referred to as the "Reporting Period").
In accordance with the "Company Law of the People's Republic of China," the "Securities Law of the People's Republic of China," the "Administrative Measures for Major Asset Reorganizations of Listed Companies," the "Regulatory Guidelines for Listed Companies No. 9 — Regulatory Requirements for the Planning and Implementation of Major Asset Reorganizations by Listed Companies," and other relevant laws, regulations, and provisions of the China Securities Regulatory Commission, this Firm hereby issues this "Beijing Dentons Law Offices Supplementary Legal Opinion (I) on the Major Asset Purchase by Wuhan Mingde Bio-Tech Co., Ltd." (hereinafter referred to as "this Supplementary Legal Opinion") regarding the legal issues raised in the "Inquiry Letter" and major legal matters involving the major asset reorganization during the period from January 1, 2026, to March 31, 2026 (hereinafter referred to as the "Supplementary Verification Period").
This Supplementary Legal Opinion serves as a supplement to the "Legal Opinion"; in the event of any inconsistency, this Supplementary Legal Opinion shall prevail. The statements made by this Firm in the "Legal Opinion" apply to this Supplementary Legal Opinion.
Unless otherwise indicated by the context, the abbreviations used in this Supplementary Legal Opinion have the same meanings as those used in the "Legal Opinion" and the "Report (Draft) on the Major Asset Purchase by Wuhan Mingde Bio-Tech Co., Ltd."
This Firm and its signing lawyers have strictly performed their statutory duties and adhered to the principles of diligence and good faith in accordance with the "Securities Law," the "Administrative Measures for Law Firms Engaging in Securities Legal Business," and the "Practice Rules for Law Firms Engaging in Securities Legal Business (Trial)," and have conducted necessary verification to ensure that the facts recognized in this Supplementary Legal Opinion are true, accurate, and complete, and that the conclusions reached are legal and accurate, without false records, misleading statements, or major omissions, and we assume corresponding legal liability.
This Firm expresses opinions only on legal issues related to the Company's transaction and does not express opinions on non-legal professional matters such as accounting, auditing, and valuation. When citing certain data and conclusions from accounting reports, audit reports, and asset valuation reports in this Supplementary Legal Opinion, this Firm has fulfilled its necessary duty of care, but such citations do not constitute any express or implied guarantee by this Firm regarding the truthfulness and accuracy of such data and conclusions.